Mereo BioPharma Group (MREO) Competitors $1.85 +0.03 (+1.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.85 +0.00 (+0.22%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MREO vs. UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, QURE, ATAI, and CRONShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Its Competitors Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group Mereo BioPharma Group (NASDAQ:MREO) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Does the media favor MREO or UPB? In the previous week, Upstream Bio had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for Upstream Bio and 2 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.64 beat Upstream Bio's score of 1.15 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MREO or UPB more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A -80.00% -66.94% Upstream Bio -3,836.58%-35.90%-26.26% Do institutionals & insiders believe in MREO or UPB? 62.8% of Mereo BioPharma Group shares are held by institutional investors. 5.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 13.6% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend MREO or UPB? Mereo BioPharma Group currently has a consensus price target of $7.40, indicating a potential upside of 300.00%. Upstream Bio has a consensus price target of $56.50, indicating a potential upside of 221.57%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, MREO or UPB? Mereo BioPharma Group has higher revenue and earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M29.42-$43.25M-$0.07-26.43Upstream Bio$2.72M347.84-$62.81MN/AN/A SummaryMereo BioPharma Group beats Upstream Bio on 8 of the 13 factors compared between the two stocks. Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.15M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-26.4321.5775.5626.02Price / Sales29.42254.90461.6291.38Price / CashN/A44.4425.8129.91Price / Book4.749.6112.726.25Net Income-$43.25M-$53.29M$3.29B$270.76M7 Day Performance3.35%0.57%0.84%2.54%1 Month Performance6.32%4.56%4.67%5.73%1 Year Performance-56.78%10.44%69.02%25.85% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group2.3317 of 5 stars$1.85+1.6%$7.40+300.0%-56.8%$294.15M$10M-26.4340Positive NewsUPBUpstream Bio1.8329 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038Positive NewsSIONSionna Therapeutics2.7945 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035High Trading VolumeORICOric Pharmaceuticals4.5608 of 5 stars$10.50-3.5%$17.29+64.6%+9.0%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.2355 of 5 stars$14.80-3.0%$30.00+102.7%+95.7%$1.05B$297.20M-113.85280News CoverageShort Interest ↑SYRESpyre Therapeutics2.2671 of 5 stars$16.63-2.2%$53.40+221.1%-46.7%$1.03B$890K-4.8973Positive NewsSPRYARS Pharmaceuticals2.5996 of 5 stars$10.70+6.3%$32.50+203.7%-24.6%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.2872 of 5 stars$40.75-13.0%$85.88+110.7%-37.0%$985.99M$8.55M-3.32110Positive NewsGap DownHigh Trading VolumeQUREuniQure3.214 of 5 stars$17.43-2.9%$37.45+114.9%+191.3%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.8782 of 5 stars$4.52-1.1%$11.25+148.9%+256.2%$979.53M$2.31M-6.5580Positive NewsCRONCronos Group2.4744 of 5 stars$2.48-0.8%N/A+16.1%$957.23M$117.61M49.60450 Related Companies and Tools Related Companies UPB Competitors SION Competitors ORIC Competitors PHAR Competitors SYRE Competitors SPRY Competitors PRAX Competitors QURE Competitors ATAI Competitors CRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MREO) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
